

**S4 Table.** Univariate analysis of survival in sorafenib-treated patients with intermediate-stage hepatocellular carcinoma

| Variables   | Univariate analysis |             | <i>P</i> |
|---|---------------------|-------------|----------|
|   | Hazard ratio        | 95% CI      |          |
| <b>Gender, male</b>                                       |                     |             |          |
| Absent  | Reference           |             |          |
| Present   | 1.137               | 0.577–2.210 | 0.710    |
| <b>Age, &gt;72 years</b>                                  |                     |             |          |
| Absent  | Reference           |             |          |
| Present   | 0.818               | 0.456–1.468 | 0.501    |
| <b>HBV</b>  |                     |             |          |
| Absent  | Reference           |             |          |
| Present   | 1.409               | 0.427–4.650 | 0.573    |
| <b>HCV</b>  |                     |             |          |
| Absent  | Reference           |             |          |
| Present   | 0.960               | 0.521–1.768 | 0.895    |
| <b>Alcohol abuse</b>                                      |                     |             |          |
| Absent  | Reference           |             |          |
| Present   | 0.458               | 0.062–3.363 | 0.443    |
| <b>ECOG-PS, &gt;0</b>                                     |                     |             |          |
| Absent  | Reference           |             |          |
| Present   | 1.810               | 1.009–3.245 | 0.046    |
| <b>Child–Pugh B</b>                                       |                     |             |          |
| Absent  | Reference           |             |          |
| Present   | 2.083               | 1.092–3.974 | 0.026    |
| <b>Maximum size of the intrahepatic lesion, &gt;50 mm</b> |                     |             |          |
| Absent  | Reference           |             |          |
| Present   | 1.302               | 0.684–2.479 | 0.421    |
| <b>Number of intrahepatic lesions, &gt;7</b>              |                     |             |          |
| Absent  | Reference           |             |          |
| Present   | 1.332               | 0.697–2.546 | 0.386    |
| <b>AFP, &gt;400 ng/mL</b>                                 |                     |             |          |
| Absent  | Reference           |             |          |
| Present   | 3.474               | 1.839–6.562 | <0.001   |
| <b>Stage progression process</b>                          |                     |             |          |
| Initial diagnosis as intermediate stage                   | Reference           |             |          |
| Initial diagnosis as early stage                          | 0.958               | 0.536–1.711 | 0.884    |
| <b>Average daily dose, ≤400 mg/day</b>                    |                     |             |          |
| Absent  | Reference           |             |          |
| Present   | 1.223               | 0.666–2.247 | 0.517    |

Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; ECOG-PS, Eastern Cooperative Oncology Group performance status; MVI, macrovascular invasion; EHM, extrahepatic metastasis; AFP, alpha-fetoprotein